行情

SYRS

SYRS

Syros Pharms
NASDAQ

实时行情|Nasdaq Last Sale

9.44
+0.73
+8.38%
交易中 15:07 10/15 EDT
开盘
8.71
昨收
8.71
最高
9.67
最低
8.70
成交量
13.41万
成交额
--
52周最高
11.93
52周最低
5.17
市值
4.01亿
市盈率(TTM)
-4.8237
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SYRS 新闻

  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.50分钟前
  • 一文看懂谷歌秋季发布会:AI串联全家桶
  • 新浪科技.1小时前
  • 高盛表示已将持有的WeWork股权减记了8000万美元
  • 新浪美股.1小时前
  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前

更多

所属板块

制药
+1.13%
制药与医学研究
+1.30%

热门股票

名称
价格
涨跌幅

SYRS 简况

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
展开

Webull提供Syros Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。